Episode Summary
Executive Summary: Peter Attia and Dexcom CEO Kevin Sayer discuss why The Drive is listener-supported, then dive deep into continuous glucose monitoring (CGM): how Dexcom’s sensors work, why G6 improved accuracy and usability, the economics and reimbursement hurdles, and how CGM is expanding from type 1 diabetes into type 2, gestational diabetes, hospitals, and wellness. They also cover future algorithms, smartwatch integration, and the behavioral power of real-time glucose feedback.
Main Topics: Why The Drive is ad-supported by listeners, not ads (Priority: 4/5): Attia explains the podcast’s membership model as a trust-preserving alternative to advertising, emphasizing honesty, independence, and added value through show notes, transcripts, AMAs, and product discounts. Kevin Sayer’s path to Dexcom and company culture (Priority: 4/5): Sayer recounts his career in diabetes and medical devices, his board role, and eventual move to Dexcom, highlighting a curious, startup-like culture that values experimentation, employee engagement, and rapid learning. How CGM works and why Dexcom G6 improved performance (Priority: 5/5): The discussion explains the electrochemical sensor, subcutaneous filament, transmitter, and algorithmic conversion to glucose values, plus how G6 improved insertion, membrane technology, and algorithms to boost accuracy and comfort. Clinical value in type 1 and type 2 diabetes (Priority: 5/5): They discuss CGM’s impact on A1C, hypoglycemia prevention, shared alerts, and behavioral change, with special focus on type 1 diabetes, intensive-insulin type 2 diabetes, and the need for better outcomes beyond glucose alone. Reimbursement, regulation, and the U.S. healthcare system (Priority: 5/5): Sayer explains insurance coverage, Medicare/CMS policy, durable medical equipment classification, seasonal purchasing patterns, and why prescription and FDA rules currently limit over-the-counter use. Future products: algorithms, partnerships, and new markets (Priority: 4/5): They cover Dexcom’s collaboration with Verily/Google, Apple Watch integration, direct-to-watch plans, automated insulin delivery, decision-support algorithms, and potential expansion into hospitals, gestational diabetes, and wellness. Behavior change through real-time feedback (Priority: 5/5): Attia argues CGM changes eating and lifestyle decisions more powerfully than periodic lab tests, using personal examples like trail mix, grapes, exercise, sleep, and stress to show how immediate feedback alters behavior.
Key Arguments: CGM is valuable because it provides immediate, actionable feedback that changes behavior in ways delayed metrics like A1C cannot. Dexcom’s competitive edge is built on performance, patient convenience/usability, and cost reduction, in that order. G6’s improved accuracy comes from multiple factors: easier insertion, new membrane technology, a better algorithm, and a flatter, less traumatic design. Real-time alerts and sharing features can prevent dangerous hypoglycemia and reduce hospitalizations, especially for hypoglycemia-unaware patients. CGM is underpenetrated in type 1 diabetes and has major growth potential in insulin-using type 2 diabetes, gestational diabetes, hospitals, and wellness. The U.S. reimbursement system creates major friction because payers focus on short-term costs while CGM benefits often accrue over years and across insurance plans. Dexcom’s future is increasingly software-driven: algorithms, decision support, and integration with pumps, watches, and other platforms will matter as much as the sensor itself.
Data Points: Date of interview: September 21, 2018 - Forward-looking statement disclaimer read before the interview Dexcom market cap: $12 billion - Attia references Dexcom’s size near the end of the conversation Dexcom employees: 2,500 full-time employees plus several hundred temps - Sayer describes company growth and manufacturing staffing Type 1 diabetes population in the U.S.: About 1 million to 1.5 million (literature range 1.3–2 million) - Sayer estimates the addressable population Type 2 diabetes patients on intensive insulin: About 1.5 million - Sayer identifies another major CGM market Current CGM penetration in type 1 diabetes: 20%–30% - Sayer says the market is still far from saturated Desired future penetration in type 1 intensive population: 80% - Sayer states his public goal for CGM adoption A1C improvement with CGM: At least 0.5 percentage points over 12 months; about 1.0 point in some six-month independent use comparisons - Sayer cites company studies showing improved glycemic control Hospitalization cost for severe hypoglycemia: $10,000–$30,000 - Attia and Sayer discuss acute cost savings from preventing lows Sensor wear duration: 10 days - Dexcom G6 sensor duration discussed repeatedly Sensor insertion depth: About half an inch under the skin - Sayer explains the subcutaneous placement of the filament Transmission range: 20 feet - Sayer notes labeled Bluetooth range and connectivity limitations Average cash cost: About $9–$11 per day - Attia and Sayer discuss out-of-pocket pricing for cash-pay users Average recognized revenue per sensor: $70–$75 - Sayer references historical pricing/revenue recognition Medicare approval timing: January 2017 - Sayer notes CMS approval for intensive insulin-using type 2 patients Medicare phone-app approval delay: About 18 months - Sayer describes the lag before Medicare patients could use the phone app Employee survey length: Almost 200 pages of comments - Sayer uses this to illustrate engagement and culture Company growth: Added more than 1,500 employees in the last two years - Sayer describes rapid scaling Fingersticks in ICU example: 48 finger sticks in 24 hours - Sayer and Attia discuss hospital glucose monitoring burden CGM calibration issue with G5: G6 removed the need for routine calibrations - Attia contrasts G5 and G6 user experience Personal wear frequency: 300 to 330 days per year - Attia says he wears his CGM nearly all the time
Pivotal Quotes: "I have a really hard time advocating for something that I'm not absolutely nuts for." — Kevin Sayre: Explaining why he prefers not to sell ads and instead only endorse products he truly believes in "We call that the unicorn." — Kevin Sayre: Describing the rare but gratifying moments when CGM and fingerstick readings match exactly "If it's accurate, if you solve the accuracy problem, if you make it more convenient and solve the convenient problem, if you lower the cost, and finally if you can produce a health care outcome, you have something that's meaningful." — Kevin Sayre: Summarizing Dexcom’s framework for product development and market success
Implications: CGM is moving from niche diabetes management toward a broader real-time metabolic platform. The winners will combine accuracy, usability, affordability, and software-driven insights while navigating reimbursement and regulatory constraints.
About Peter Attia Drive
Expert insight on health, performance, longevity, critical thinking, and pursuing excellence. Dr. Peter Attia (Stanford/Hopkins/NIH-trained MD) talks with leaders in their fields.